Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607310 | 0.81 | LMNA (0.46) | CYP1A2CYP2D6MAPTPIK3CBPIK3CA | |
| SCHEMBL3600101 | 0.79 | PIK3CB (0.51) | PIK3CBPIK3CAKMT2ALMNAHTT | |
| SCHEMBL3604776 | 0.77 | ATR (0.59) | PIK3CBPIK3CAPIK3CG | |
| SCHEMBL3605489 | 0.77 | ALDH1A1 (0.43) | CYP1A2CYP2D6MAPTPIK3CBPIK3CA | |
| SCHEMBL3600948 | 0.73 | PIK3CB (0.54) | PIK3CBPIK3CAKMT2ALMNAHTT | |
| SCHEMBL17859942 | 0.71 | CYP1A2 (0.54) | CYP1A2CYP2D6MAPTPIK3CBKMT2A | |
| SCHEMBL12485821 | 0.70 | KMT2A (0.47) | CYP1A2CYP2D6MAPTKMT2APOLB | |
| SCHEMBL17654953 | 0.70 | EPHX2 (0.33) | CYP1A2CYP2D6 | |
| SCHEMBL3938069 | 0.70 | CYP1A2 (0.49) | CYP1A2CYP2D6MAPTPIK3CBPIK3CA | |
| SCHEMBL2493395 | 0.70 | CYP1A2 (0.49) | CYP1A2CYP2D6MAPTPIK3CBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| EP-2146981-A1 | PHARMACEUTICAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125833-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, JAK2 | CYP1A2 1185/4885CYP2D6 1107/4885MAPT 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.